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We would like to thank Dr. Chen and his colleagues for 
their interest in our study. We are grateful for the insightful 
comments of our manuscript and we are happy to respond 
to them.
Extubation failure is an independent predictor of 
mortality. The development of therapies for preventing this 
has been focused on specific causes of reintubation [corticoid 
for larynx edema and noninvasive ventilation (NIV) for the 
hypercapnic respiratory failure in patients with pulmonary 
chronic diseases] and in patients with risk factors associated 
with extubation failure. Usually, extubated patients receive 
conventional oxygentherapy for correcting the oxygenation 
impairment. This system provides low-flow and doesn’t 
guarantee the fraction of inspired oxygen (FiO2).
As discussed in detail in your paper, the high-flow 
nasal cannula (HFNC) generates several physiological 
effects. This mode now allows constant FiO2 during all 
the respiratory cycle, it confers a low level of continuous 
positive airway pressure proportional to administrated 
flow which reduces work of breathing and increased end-
expiratory lung volume, partly through intrinsic positive 
end-expiration pressure compensation and dead-space 
washout. The effect of HFNC on carbon dioxide clearance 
is uncertain in chronic hypercapnic patients, but has been 
described in ear, nose and throat surgical patients under 
apneic conditions, suggesting that dead space washout must 
be accompanied by some degree of alveolar ventilation, as 
apneic time rises up to 35 minutes (1). In addition, HFNC 
provided heated and humidified oxygen, which improves 
comfort and possibly reduces airway inflammation and 
facilitates the drainage of respiratory secretions. Gas 
conditioning has demonstrated in experimental research 
a potentially protective effect on respiratory mucosa. 
In addition, clinical trials report an improvement in the 
ability to clear respiratory secretions (2,3). Regarding our 
methodology of the study, HFNC was applied before the 
extubation to block the entrance of dry and cold air in the 
patients’ native airway from the beginning. Although this 
is speculative, it could play a major role in the early benefit 
that we found in the lower rate of upper airway obstruction 
(laryngeal edema requiring reintubation which wasn’t 
described in the HFNC group).
In our study (3), we aimed to evaluate whether high-
flow oxygen therapy after planned extubation would reduce 
the need for reintubation compared with standard oxygen 
therapy in patients at low risk for reintubation. The All-
cause reintubation within 72 hours was lower in the high-
flow group (4.9% vs. 12.2%). This difference was mainly 
attributable to a lower incidence of respiratory-related 
reintubation in the high-flow group (1.5% vs. 8.7%). 
The main benefit was observed on reducing reintubation 
secondary to hypoxemia and inability to clear secretions (3). 
These results agree with those obtained by Maggiore et al. (2).
We classified patients according to the criteria for risk 
of reintubation. We didn’t use the type of the respiratory 
failure considering that we searched for the HFNC 
preventive function and not the treatment once that the 
failure was present. Today it’s unclear how identify at-risk 
patients for extubation failure. Previous trials, like Thille 
et al.’s study (4), have tried to set up the underlying risks 
of extubation outcome. In keeping with these studies, we 
included ten risk factors. In our opinion, our strict criteria 
clearly select a low-risk population.
Simultaneously, we compared HFNC with NIV in 
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patients at high risk for reintubation in a non-inferiority 
trial (5). While studies have suggested that prophylactic 
NIV could prevent postextubation respiratory failure, they 
appear inconsistent with regard to reintubation. However, 
Thille et al. (6) adds new data supporting the benefit of 
NIV for this indication. In a general population of critical 
patients it hasn’t been proved (7), for that reason in the 
low-risk group it was compared to conventional oxygen 
therapy.
Regarding the study protocol, patients who tolerated 
the spontaneous breathing trial were reconnected with 
the previous ventilator settings for rest (8) and clinical 
evaluation of the airway patency. Flow was initially set 
at 10 L/min and titrated upward in 5 L/min steps until 
patients experienced discomfort. Twelve hours after 
extubation a steady sate is usually obtained. In our study 
we observed a tolerated main gas-flow of 31 L/min, a 
moderate flow, suggesting that under these conditions the 
flow tolerated is a marker of severity. After 24 hours, high-
flow therapy was stopped and, if necessary, patients received 
conventional oxygen therapy. In our preliminary study (9), 
gas-flow >35 L/min 12 hours after extubation predicted 
reintubation; unfortunately, this results was not reproduced 
in the trial. Results in the high-risk group, could elucidate 
the role of the tolerated flow according with the risk of 
failure. 
Our study is similar to a pragmatic study, considering 
that we try to evaluate the HNFC efficacy under real and 
no ideal circumstances. Therefore, HFNC was applied 
24 hours after extubation because 24 hours is the standard 
monitoring time before ICU discharge after a planned 
extubation. The 24-hour time limit can restrict HFNC 
effects to this time period (2). Nevertheless, the results 
confirmed that 24 hours was enough to reduce the rate of 
reintubation. Our 24-hour limit probably helped physicians 
appreciate undertreated respiratory distress at an early 
stage and not delay the reintubation. This could be possible 
because HFNC increases comfort, oxygenation and being 
able to disguise respiratory distress. In fact, as suggested 
by Kang et al. (10), applying HFNC in patients with 
respiratory failure according to clinical response could lead 
to delayed intubation. This could be associated with a worse 
outcome, as has been shown with NIV. HFNC doesn’t 
delay the reintubation under the conditions of our protocol. 
We attribute this result to the preventive intention, the 
fixed period and to the predefined reintubation criteria. We 
consider that this is our study’s main safety variable. Even 
so, we are waiting to see if this safety is confirmed in the 
high-risk group.
We agree with Dr. Chen and colleagues that further trials 
are needed to evaluate the pathophysiological mechanism 
of extubation failure and the HFNC physiological effects in 




Provenance: This is an invited article commissioned by the 
Section Editor Zhongheng Zhang (Department of Critical 
Care Medicine, Jinhua Municipal Central Hospital, Jinhua 
Hospital of Zhejiang University, Jinhua, China).
Conflicts of Interest: Dr. Hernández reported travel expenses 
and personal fees from Fisher & Paykel. The other authors 
have no conflicts of interest to declare.
Response to: Chen L, Li HL, Brochard L. High-flow nasal 
cannula in postextubation management. J Thorac Dis 
2016;8:E1013-6.
References
1. Patel A, Nouraei SA. Transnasal Humidified Rapid-
Insufflation Ventilatory Exchange (THRIVE): a 
physiological method of increasing apnoea time in patients 
with difficult airways. Anaesthesia 2015;70:323-9.
2. Maggiore SM, Idone FA, Vaschetto R, et al. Nasal high-
flow versus Venturi mask oxygen therapy after extubation. 
Effects on oxygenation, comfort, and clinical outcome. Am 
J Respir Crit Care Med 2014;190:282-8.
3. Hernández G, Vaquero C, González P, et al. Effect 
of Postextubation High-Flow Nasal Cannula vs 
Conventional Oxygen Therapy on Reintubation in Low-
Risk Patients: A Randomized Clinical Trial. JAMA 
2016;315:1354-61.
4. Thille AW, Harrois A, Schortgen F, et al. Outcomes of 
extubation failure in medical intensive care unit patients. 
Crit Care Med 2011;39:2612-8.
5. Hernandez G, Vaquero C, Gonzalez P, et al. High flow 
conditioned oxygen therapy for prevention of reintubation 
in critically ill patients at high risk for extubation failure: 
a multicenter randomised controlled trial. Intensive Care 
Med Exp 2015;3:A823.
6. Thille AW, Boissier F, Ben-Ghezala H, et al. Easily 
E1431Journal of Thoracic Disease, Vol 8, No 10 October 2016
© Journal of Thoracic Disease. All rights reserved.   J Thorac Dis 2016;8(10):E1429-E1431jtd.amegroups.com
identified at-risk patients for extubation failure may benefit 
from noninvasive ventilation: a prospective before-after 
study. Crit Care 2016;20:48.
7. Glossop AJ, Shephard N, Bryden DC, et al. Non-
invasive ventilation for weaning, avoiding reintubation 
after extubation and in the postoperative period: a meta-
analysis. Br J Anaesth 2012;109:305-14.
8. Hernandez G, Fernandez R, Luzon E, et al. The early 
phase of the minute ventilation recovery curve predicts 
extubation failure better than the minute ventilation 
recovery time. Chest 2007;131:1315-22.
9. Hernandez G, Collado CV, Plaza SG, et al. High 
Flow Conditioned Oxygen Therapy for Prevention of 
Reintubation in Critically Ill Patients: A Preliminary 
Cohort Study. Int J Crit Care Emerg Med 2015;1:2.
10. Kang BJ, Koh Y, Lim CM, et al. Failure of high-flow 
nasal cannula therapy may delay intubation and increase 
mortality. Intensive Care Med 2015;41:623-32.
Cite this article as: Colinas L, Canabal A, Hernández G. 
Reducing reintubation and postextubation respiratory failure: 
improving high-flow oxygen support performance. J Thorac 
Dis 2016;8(10):E1429-E1431. doi: 10.21037/jtd.2016.10.31
